CLIMB BIO, INC. Net Income
CLIMB BIO, INC. (CLYM) reported Net Income of -$13.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- CLIMB BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$13.50M.
- CLIMB BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$13.72M.
- CLIMB BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$17.52M.
- CLIMB BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$12.89M.
- CLIMB BIO, INC. net income (loss) attributable to parent for fiscal 2025 was -$59.85M.
- CLIMB BIO, INC. net income (loss) attributable to parent for fiscal 2024 was -$73.90M.
- CLIMB BIO, INC. net income (loss) attributable to parent for fiscal 2023 was -$35.12M.
- CLIMB BIO, INC. net income (loss) attributable to parent for fiscal 2022 was -$45.24M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.50M 10-Q · filed 2026-08-06 | -$27.22M 10-Q · filed 2026-08-06 | -$44.74M derived: sum of 3 quarters · filed 2026-08-06 | -$57.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$13.72M 10-Q · filed 2026-08-06 | -$31.24M derived: sum of 2 quarters · filed 2026-08-06 | -$44.13M derived: sum of 3 quarters · filed 2026-08-06 | -$52.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$17.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$30.40M derived: sum of 2 quarters · filed 2026-03-05 | -$39.07M derived: sum of 3 quarters · filed 2026-08-06 | -$59.85M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$12.89M 10-Q · filed 2025-11-06 | -$21.55M derived: sum of 2 quarters · filed 2026-08-06 | -$42.34M 10-Q · filed 2025-11-06 | -$50.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$8.67M 10-Q · filed 2026-08-06 | -$29.45M 10-Q · filed 2026-08-06 | -$37.86M derived: sum of 3 quarters · filed 2026-08-06 | -$46.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.78M 10-Q · filed 2026-08-06 | -$29.20M derived: sum of 2 quarters · filed 2026-08-06 | -$38.09M derived: sum of 3 quarters · filed 2026-08-06 | -$92.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$17.31M derived: sum of 2 quarters · filed 2026-03-05 | -$72.20M derived: sum of 3 quarters · filed 2026-03-05 | -$73.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$8.89M 10-Q · filed 2025-11-06 | -$63.78M derived: sum of 2 quarters · filed 2025-11-06 | -$65.48M 10-Q · filed 2025-11-06 | -$69.12M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$54.89M 10-Q · filed 2025-11-06 | -$56.59M 10-Q · filed 2025-08-12 | -$60.23M derived: sum of 3 quarters · filed 2025-11-06 | -$64.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$1.70M 10-Q · filed 2025-11-06 | -$5.34M derived: sum of 2 quarters · filed 2025-11-06 | -$9.31M derived: sum of 3 quarters · filed 2025-11-06 | -$14.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | -$3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$7.61M derived: sum of 2 quarters · filed 2025-03-25 | -$12.83M derived: sum of 3 quarters · filed 2025-03-25 | -$35.12M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$3.97M 10-Q · filed 2024-11-12 | -$9.19M derived: sum of 2 quarters · filed 2024-11-12 | -$31.48M 10-Q · filed 2024-11-12 | -$39.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$5.22M 10-Q · filed 2024-08-14 | -$27.51M 10-Q · filed 2024-08-14 | -$35.27M derived: sum of 3 quarters · filed 2024-08-14 | -$44.95M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$22.29M 10-Q · filed 2024-05-15 | -$30.05M derived: sum of 2 quarters · filed 2024-05-15 | -$39.73M derived: sum of 3 quarters · filed 2024-05-15 | -$54.33M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$17.44M derived: sum of 2 quarters · filed 2024-03-28 | -$32.04M derived: sum of 3 quarters · filed 2024-03-28 | -$45.24M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$9.68M 10-Q · filed 2023-11-14 | -$24.28M derived: sum of 2 quarters · filed 2023-11-14 | -$37.48M 10-Q · filed 2023-11-14 | -$48.03M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$14.60M 10-Q · filed 2023-08-10 | -$27.80M 10-Q · filed 2023-08-10 | -$38.34M derived: sum of 3 quarters · filed 2023-08-10 | -$47.96M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.20M 10-Q · filed 2023-05-11 | -$23.75M derived: sum of 2 quarters · filed 2023-05-11 | -$33.36M derived: sum of 3 quarters · filed 2023-05-11 | -$42.08M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$10.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$20.16M derived: sum of 2 quarters · filed 2023-03-06 | -$28.88M derived: sum of 3 quarters · filed 2023-03-06 | -$47.48M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$9.62M 10-Q · filed 2022-11-14 | -$18.33M derived: sum of 2 quarters · filed 2022-11-14 | -$36.94M 10-Q · filed 2022-11-14 | -$51.80M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$8.72M 10-Q · filed 2022-08-15 | -$27.32M 10-Q · filed 2022-08-15 | -$42.18M derived: sum of 3 quarters · filed 2022-08-15 | -$44.44M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$18.60M 10-Q · filed 2022-05-16 | -$33.46M derived: sum of 2 quarters · filed 2022-05-16 | -$35.72M derived: sum of 3 quarters · filed 2022-05-16 | -$37.35M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$17.12M derived: sum of 2 quarters · filed 2022-03-07 | -$18.75M derived: sum of 3 quarters · filed 2022-03-07 | -$20.67M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$2.26M 10-Q · filed 2021-11-08 | -$3.89M derived: sum of 2 quarters · filed 2021-11-08 | -$5.80M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$1.63M 10-Q · filed 2021-09-13 | -$3.55M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |